Lipopolysaccharide-Induced Bone Loss in Rodent Models: A Systematic Review and Meta-Analysis

Abstract

Osteoporosis has traditionally been characterized by underlying endocrine mechanisms, though evidence indicates a role of inflammation in its pathophysiology. Lipopolysaccharide (LPS), a component of gram‐negative bacteria that reside in the intestines, can be released into circulation and stimulate the immune system, upregulating bone resorption. Exogenous LPS is used in rodent models to study the effect of systemic inflammation on bone, and to date a variety of different doses, routes, and durations of LPS administration have been used. The study objective was to determine whether systemic administration of LPS induced inflammatory bone loss in rodent models. A systematic search of Medline and four other databases resulted in a total of 110 studies that met the inclusion criteria. Pooled standardized mean differences (SMDs) and corresponding 95% confidence intervals (CI) with a random‐effects meta‐analyses were used for bone volume fraction (BV/TV) and volumetric bone mineral density (vBMD). Heterogeneity was quantified using the I2 statistic. Shorter‐term (<2 weeks) and longer‐term (>2 weeks) LPS interventions were analyzed separately because of intractable study design differences. BV/TV was significantly reduced in both shorter‐term (SMD = −3.79%, 95% CI [−4.20, −3.38], I2 62%; p < 0.01) and longer‐term (SMD = −1.50%, 95% CI [−2.00, −1.00], I2 78%; p < 0.01) studies. vBMD was also reduced in both shorter‐term (SMD = −3.11%, 95% CI [−3.78, −2.44]; I2 72%; p < 0.01) and longer‐term (SMD = −3.49%, 95% CI [−4.94, −2.04], I2 82%; p < 0.01) studies. In both groups, regardless of duration, LPS negatively impacted trabecular bone structure but not cortical bone structure, and an upregulation in bone resorption demonstrated by bone cell staining and serum biomarkers was reported. This suggests systemically delivered exogenous LPS in rodents is a viable model for studying inflammatory bone loss, particularly in trabecular bone. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Bacterial Lipopolysaccharides Exacerbate Neurogenic Heterotopic Ossification Development

“…Interestingly, the anabolic effect of LPS in our model of SCI‐induced intramuscular NHO is in contrast to other reports showing that (i) chronic LPS administration in mice leads to skeletal bone loss, mostly by increasing osteoclastogenesis as recently reviewed in a meta‐analysis, ( 61 ) and (ii) that addition of LPS in cultures of the mouse pro‐osteoblastic immortalized cell line MC3T3‐E1 ( 62 ) or primary calvarial osteoblasts ( 63 ) reduces expression of osteoblasts markers. However, a number of articles have also shown that LPS can have an anabolic effect on mesenchymal progenitor cells isolated from human bone marrow, ( 64 ) umbilical cord blood, ( 65 ) periodontal ligaments, ( 66 ) mouse bone marrow, ( 67 ) and increases expression of osteoblast markers and mineralization.…”

Colon-targeted Engineered Postbiotics Nanoparticles Alleviating Osteoporosis through Gut-Bone Axis

“…As a major Gram-positive bacteria cell wall component, LTA is related to various in ammatory diseases 22 . With the increased level of LPS in the circulation, systemic in ammation can be activated, which will induce bone loss 23 . Herein, to investigate the underlying correlation between GI and skeletal system after B@S treatment, we veri ed serum LPS and LTA concentration by enzyme-linked immunosorbent assay (ELISA).…”

Glycogen Synthase Kinase-3 Beta (GSK3β) as a Potential Drug Target in Regulating Osteoclastogenesis: An Updated Review on Current Evidence

“…In a murine clavarial model of titanium-induced bone destruction, histological analysis showed that the eroded surface (ES), TRAP-positive multinucleated cells, and Oc.S were increased [26]. Lipopolysaccharides, a surface membrane component of gram-negative bacteria, is another potent inducer of bone resorption, upregulating osteoclast differentiation and its activities [27]. In in vivo studies, the group receiving LPS displayed a higher number of TRAP-positive osteoclasts and expression of osteoclastogenic markers [including RANKL, NFATc1, Fos proto-oncogene (c-Fos), MMP-9, CTSK, and TRAF6], as well as a higher level of inflammatory markers [interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)].…”